Breast cancer is the most frequent form of cancer and leading cause of cancer-related deaths among women around the world ([@R1]). The cancer accounts for almost one quarter of new cancer cases annually ([@R2]), and the incidence continues to increase rapidly, both in China and worldwide ([@R3]). Although it has been well-established that breast carcinogenesis is a result of the complex interactions between multiple environmental and genetic factors, the mechanisms of the oncogenesis at the molecular level remain poorly understood. Genetic factors can serve as a susceptibility variable for breast cancer development, and their identification can help to reduce the incidence of breast cancer ([@R4]). However, several breast cancer susceptibility genes identified so far, such as *BRCA1* and *BRCA2*, account for only less than 5% of the total breast cancer incidence ([@R5]).

Single nucleotide polymorphisms (SNPs) have been extensively investigated for their associations with the risk of various cancers ([@R6]-[@R11]). As inflammation is caused by a molecular network underlying breast carcinogenesis ([@R12]), we propose that SNPs within inflammatory response genes could modify breast cancer predisposition risk. The associations of various inflammatory response gene polymorphisms with breast cancer risk in the Chinese population, especially the East Chinese population, have been understudied. In the current study, we investigated the associations of *NFKB1* c.-798\_-795delATTG (rs28362491), *NFKBIA* c.-949C\>T (rs2233406), *IL-8* c.-352A\>T (rs4073), *IL-10* c.-854T\>C (rs1800871), *TNF* c.-418G\>A (rs361525), and *TNF* c.-488G\>A (rs1800629) polymorphisms with breast cancer risk in East China. Since all these polymorphisms are located in the promoter region, they could affect the transcriptional activity of the gene, resulting in enhanced or reduced cDNA, and eventually protein levels, among their carriers ([@R6],[@R7],[@R13]). In addition, despite the relatively well established associations of the polymorphisms with cancer risks in other populations ([@R6]-[@R9]), little is known about their association with breast cancer risk in East China population, which further motivated us to undertake this research.

Patients and methods
====================

Study participants and ethical considerations
---------------------------------------------

A total of 1032 female study participants -- 514 breast cancer patients and 518 controls without cancer were identified at the Jiujiang First People's Hospital. 474 breast cancer patients and 501 female controls without cancer agreed to participate in the study. The participants were interviewed by trained professionals and data related to smoking, oral contraceptive use, and menopausal status were collected. The patients' histopathological types and cancer grading were retrieved from their medical records. All the participants were Han Chinese. The study received approval from the Ethics of Human Research Board of Jiujiang First People's Hospital. Informed consent was obtained from the participants before inclusion in the study.

Genotyping
----------

Polymorphisms were genotyped on the DNA isolated from the peripheral blood samples using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique and the genotypes were verified by direct sequencing of PCR products. For *NFKB1* c.-798\_-795delATTG (rs28362491), the PCR primers used were 5′-TGG GCA CAA GTC GTT TAT GA-3′ and 5′-CTG GAG CCG GTA GGG AAG-'3 ([@R6]) and the annealing temperature was 63.5°C. The PCR product 281 bp (deletion allele) or 285 bp (insertion allele) was digested with PflMI (Van91I) restriction enzyme. The insertion genotype was identified as 2 bands on agarose gel, at 240 bp and 45 bp.

For *NFKBIA* c.-949C\>T (rs2233406) polymorphism, the forward primer was 5′-GGT CCT TAA GGT CCA ATC G-3′ and the reverse primer was 5′-GTT GTG GAT ACC TTG CAC TA-3′ ([@R7]). The annealing temperature was also 63.5°C; the 200 bp product was digested with BfaI restriction enzyme; and the CC genotype was identified as 180 + 20 bp bands.

For *IL-8* c.-352A\>T (rs4073) polymorphism, the forward primer was 5′-CCA TCA TGA TAG CAT CTG T-3′ and the reverse primer was 5′-CCA CAA TTT GGT GAA TTA TTA A-3′ ([@R8]). The annealing temperature was 57°C; the 173 bp PCR product was digested with AseI restriction enzyme; and the AA genotype was identified as 152 + 21 bp bands.

For *IL-10* c.-854T\>C (rs1800871) polymorphism, the forward primer was 5′-TGA GCA AAC TGA GGC ACA GAA AT-3′ and the reverse primer was 5′-GAC AAC ACT ACT AAG GCT CCT TTG GGA-3′ ([@R14]). The annealing temperature was 59°C; the 315 bp PCR product was digested with SspI restriction enzyme; and the TT genotype was identified as 291 + 24 bp bands.

For *TNF* c.-418G\>A (rs361525) polymorphism, the primers used were 5′-AAA CAG ACC ACA GAC CTG GTC-3′ and 5′-CTC ACA CTC CCC ATC CTC CCG GAT C-3′ ([@R15]). Annealing temperature was 59°C; the 150 bp PCR product was digested with *Bam*HI restriction enzyme; and the GG genotype was identified as 130 + 20 bp bands.

For *TNF* c.-488G\>A (rs1800629) polymorphism, the primers used were 5′-GAG GCA ATA GGT TTT GAG GGC CAT-3′ and 5′-GGG ACA CAC AAG CAT CAA G-3′ ([@R15]). The annealing temperature was 61°C; the 107 bp product was digested with NcoI restriction enzyme; and the GG genotype was identified as 87 + 20 bp bands.

Statistical analysis
--------------------

Statistical analysis was done by using SPSS, version 17.0 (SPSS Inc., Chicago, IL, USA) The differences in age, smoking habit, oral contraceptive use, menopausal status, and genotypic distribution between cases and controls were assessed using a χ^2^ test. Risk association between the polymorphisms and breast cancer was evaluated using logistic regression analysis. *P* values of \<0.05 were considered significant.

Results
=======

There were no significant differences in mean age, smoking, oral contraceptives use, and menopausal status between patients and controls ([Table 1](#T1){ref-type="table"}).

###### 

Demographic characteristics of cases with breast cancer and control participants

  Variable                              Cases        Controls     *P*
  ------------------------------------- ------------ ------------ -------
  Mean age, mean ± standard deviation   59.1 ± 7.9   59.4 ± 8.0   0.567
  Smoking, n                                                      
  Yes                                   138          137          0.540
  No                                    336          364          
  Oral contraceptive, n                                           
  Use                                   135          159          0.268
  No                                    339          342          
  Menopausal status, n                                            
  Pre                                   179          213          0.130
  Post                                  295          288          
  Histopathological type, n \*                                    
  IDC                                   346          \-           \-
  DCIS                                  71           \-           
  ILC                                   57           \-           
  Grade, n^†^                                                     
  1                                     42           \-           \-
  2                                     228          \-           
  3                                     204          \-           

\*IDC -- invasive ductal carcinoma; DCIS -- ductal carcinoma in situ; ILC -- invasive lobular carcinoma.

^†^Grade 1 -- well differentiated; Grade 2 -- moderately differentiated; Grade 3 -- poorly differentiated.

Genotype distribution
---------------------

Significant differences between cases and controls were observed for *NFKB1* ins/del and del/del genotypes, *IL-8* TT genotype, *IL-10* CC and TT genotypes, and *TNF* c.-418 and c.-488 GG and GA genotypes ([Table 2](#T2){ref-type="table"}). The two *TNF* polymorphisms were in strong linkage disequilibrium (R^2^ = 0.819). All the genotypic distributions followed Hardy-Weinberg equilibrium.

###### 

Genotype distribution of the polymorphisms in cases with breast cancer and control participants

  Gene           Genotype   Case, n/%   Controls, n/%   *P*
  -------------- ---------- ----------- --------------- ---------
  *NFKB1*        ins/ins    93/19.6     162/32.2        \<0.001
                 ins/del    210/44.3    216/43.1        0.708
                 del/del    171/36.1    123/24.6        \<0.001
  *NFKBIA*       CC         288/60.8    297/59.3        0.637
                 CT         147/31.0    162/32.3        0.657
                 TT         39/8.2      42/8.4          0.930
  *IL-8*         AA         192/40.5    186/37.1        0.281
                 AT         231/48.7    213/42.5        0.052
                 TT         51/10.8     102/20.4        \<0.001
  *IL-10*        CC         186/39.2    234/46.7        0.018
                 CT         198/41.8    219/43.7        0.054
                 TT         90/19.0     48/9.6          \<0.001
  *TNF* c.-418   GG         399/84.2    374/74.7        0.774
                 GA         69/14.6     112/22.4        0.002
                 AA         6/1.3       15/3.0          0.071
  *TNF* c.-488   GG         404/85.2    397/79.2        0.015
                 GA         66/13.9     95/19.0         0.034
                 AA         4/0.8       9/1.8           0.206

Association between the polymorphisms and breast cancer risk
------------------------------------------------------------

Significant associations were observed for at least one genotype of all the polymorphisms, with the exception of *NFKBIA* polymorphism. *NFKB1* c.-798\_-795delATTG ins/del and del/del genotypes, and *IL-10* c.-854 TT genotype were associated with increased breast cancer risk, while *IL8* c.-352 TT genotype, *TNF* c.-418 GA and AA genotypes, and c.-488 GA genotype were significantly associated with a reduced risk ([Table 3](#T3){ref-type="table"}).

###### 

Association between the polymorphisms and breast cancer risk in cases with breast cancer and control participants

  Gene           Genotype   Cases, n/%   Controls, n/%   Odds ratio (95% confidence interval)   *P*                
  -------------- ---------- ------------ --------------- -------------------------------------- ------------------ ---------
  *NFKB1*        ins/ins    93/19.6      162/32.2        \-                                     \-                 
                            ins/del      210/44.3        216/43.1                               1.69 (1.23-2.33)   0.001
                            del/del      171/36.1        123/24.6                               2.42 (1.72-3.42)   \<0.001
  *NFKBIA*       CC         288/60.8     297/59.3        \-                                     \-                 
                            CT           147/31.0        162/32.3                               0.94 (0.71-1.23)   0.637
                            TT           39/8.2          42/8.4                                 0.96 (0.60-1.52)   0.855
  *IL-8*         AA         192/40.5     186/37.1        \-                                     \-                 
                            AT           231/48.7        213/42.5                               1.05 (0.80-1.38)   0.724
                            TT           51/10.8         102/20.4                               0.48 (0.33-0.72)   \<0.001
  *IL-10*        CC         186/39.2     234/46.7        \-                                     \-                 
                            CT           198/41.8        219/43.7                               1.14 (0.87-1.50)   0.354
                            TT           90/19.0         48/9.6                                 2.36 (1.58-3.52)   \<0.001
  *TNF* c.-418   GG         399/84.2     374/74.7        \-                                     \-                 
                            GA           69/14.6         112/22.4                               0.58 (0.41-0.80)   0.001
                            AA           6/1.3           15/3.0                                 0.38 (0.14-0.98)   0.044
  *TNF* c.-488   GG         404/85.2     397/79.2        \-                                     \-                 
                            GA           66/13.9         95/19.0                                0.68 (0.48-0.96)   0.029
                            AA           4/0.8           9/1.8                                  0.44 (0.13-1.43)   0.171

Combinations of polymorphisms and their associations with breast cancer risk
----------------------------------------------------------------------------

When *NFKB1* and *NFKBIA* polymorphic genotypes were combined, positive ORs were observed for all the combinations. However, 5 out of 8 combinations showed significant association with breast cancer risk ([Table 4](#T4){ref-type="table"}) and only three combinations of *IL-8* and *IL-10* polymorphisms showed significant association with breast cancer risk ([Table 4](#T4){ref-type="table"}). Only four combinations of *TNF* c.-418 and c.-488 were analyzed due to the absence of other combinations in the study participants and two of them showed a significant association with breast cancer risk ([Table 4](#T4){ref-type="table"}).

###### 

Combination of polymorphisms and their associations with breast cancer risk in cases with breast cancer and control participants

  Genotype combination   Cases             Controls   Odds ratio (95% confidence interval)   *P*                
  ---------------------- ----------------- ---------- -------------------------------------- ------------------ ---------
  *NFKB1* ins/ins        *NFKBIA* CC       50         92                                     \-                 \-
  *NFKB1* ins/del        *NFKBIA* CC       127        127                                    1.84 (1.21-2.81)   0.004
  *NFKB1* del/del        *NFKBIA* CC       111        78                                     2.62 (1.67-4.11)   \<0.001
  *NFKB1* ins/ins        *NFKBIA* CT       33         57                                     1.07 (0.61-1.85)   0.822
  *NFKB1* ins/del        *NFKBIA* CT       66         68                                     1.79 (1.10-2.89)   0.019
  *NFKB1* del/del        *NFKBIA* CT       46         37                                     2.29 (1.32-3.98)   0.003
  *NFKB1* ins/ins        *NFKBIA* TT       9          13                                     1.27 (0.51-3.19)   0.604
  *NFKB1* ins/del        *NFKBIA* TT       16         21                                     1.40 (0.67-2.93)   0.369
  *NFKB1* del/del        *NFKBIA* TT       14         8                                      3.22 (1.26-8.20)   0.014
  *IL-8* AA              *IL-10* CC        76         93                                     \-                 \-
  *IL-8* AT              *IL-10* CC        78         93                                     1.03 (0.67-1.57)   0.905
  *IL-8* TT              *IL-10* CC        32         48                                     0.82 (0.48-1.40)   0.460
  *IL-8* AA              *IL-10* CT        82         75                                     1.34 (0.87-2.07)   0.191
  *IL-8* AT              *IL-10* CT        101        101                                    1.22 (0.81-1.84)   0.334
  *IL-8* TT              *IL-10* CT        13         43                                     0.37 (0.19-0.74)   0.005
  *IL-8* AA              *IL-10* TT        33         18                                     2.24 (1.17-4.29)   0.014
  *IL-8* AT              *IL-10* TT        48         19                                     3.09 (1.68-5.70)   \<0.001
  *IL-8* TT              *IL-10* TT        6          11                                     0.67 (0.24-1.89)   0.446
  *TNF* c.-418 GG        *TNF* c.-488 GG   399        374                                    \-                 \-
  *TNF* c.-418 GA        *TNF* c.-488 GG   3          17                                     0.17 (0.05-0.57)   0.004
  *TNF* c.-418 AA        *TNF* c.-488 GG   2          6                                      0.31 (0.62-1.56)   0.156
  *TNF* c.-418 GG        *TNF* c.-488 GA   0          0                                      N/A                N/A
  *TNF* c.-418 GA        *TNF* c.-488 GA   66         95                                     0.65 (0.46-0.92)   0.014
  *TNF* c.-418 AA        *TNF* c.-488 GA   0          0                                      N/A                N/A
  *TNF* c.-418 GG        *TNF* c.-488 AA   0          0                                      N/A                N/A
  *TNF* c.-418 GA        *TNF* c.-488 AA   0          0                                      N/A                N/A
  *TNF* c.-418 AA        *TNF* c.-488 AA   4          9                                      0.42 (0.13-1.36)   0.148

Stratification of breast cancer risk association according to menopausal status
-------------------------------------------------------------------------------

For pre-menopausal women, significant associations with breast cancer risk were observed for *NFKB1* ins/del and del/del genotypes, *NFKBIA* CT genotype, *IL-8* TT genotype, *IL-10* TT genotype, and *TNF* c.-418 GA and AA genotypes. For post-menopausal women, significant associations with breast cancer risk were observed for *NFKB1* ins/del and del/del genotypes, *IL-8* TT genotype, *IL-10* TT genotype, *TNF* c.-418 GA and AA genotypes, and *TNF* c.-488 GA genotype ([Table 5](#T5){ref-type="table"}).

###### 

Association between the polymorphisms and breast cancer risk among pre- and post-menopausal women with and without breast cancer

  Menopause   Genotype          Cases   Controls   Odds ratio (95% confidence interval)   *P*
  ----------- ----------------- ------- ---------- -------------------------------------- ---------
  Pre         *NFKB1* ins/ins   34      67         \-                                     \-
  Pre         *NFKB1* ins/del   84      90         1.84 (1.11-3.06)                       0.019
  Pre         *NFKB1* del/del   61      56         2.15 (1.24-3.72)                       0.006
  Post        *NFKB1* ins/ins   59      95         \-                                     \-
  Post        *NFKB1* ins/del   126     126        1.61 (1.07-2.42)                       0.022
  Post        *NFKB1* del/del   110     67         2.64 (1.69-4.12)                       \<0.001
  Pre         *NFKBIA* CC       119     124        \-                                     \-
  Pre         *NFKBIA* CT       44      73         0.63 (0.40-0.99)                       0.043
  Pre         *NFKBIA* TT       16      16         1.04 (0.50-2.18)                       0.913
  Post        *NFKBIA* CC       169     173        \-                                     \-
  Post        *NFKBIA* CT       103     89         1.18 (0.83-1.69)                       0.348
  Post        *NFKBIA* TT       23      26         0.91 (0.50-1.65)                       0.746
  Pre         *IL-8* AA         72      79         \-                                     \-
  Pre         *IL-8* AT         85      86         1.08 (0.70-1.68)                       0.717
  Pre         *IL-8* TT         22      48         0.50 (0.28-0.91)                       0.024
  Post        *IL-8* AA         120     107        \-                                     \-
  Post        *IL-8* AT         140     127        0.98 (0.69-1.40)                       0.924
  Post        *IL-8* TT         29      54         0.48 (0.28-0.81)                       0.006
  Pre         *IL-10* CC        73      104        \-                                     \-
  Pre         *IL-10* CT        72      92         1.11 (0.73-1.71)                       0.620
  Pre         *IL-10* TT        28      17         2.35 (1.20-4.60)                       0.013
  Post        *IL-10* CC        113     130        \-                                     \-
  Post        *IL-10* CT        120     127        1.09 (0.76-1.55)                       0.644
  Post        *IL-10* TT        62      31         2.30 (1.40-3.79)                       0.011
  Pre         *TNF* c.-418 GG   150     162        \-                                     \-
  Pre         *TNF* c.-418 GA   26      45         0.62 (0.37-1.06)                       0.082
  Pre         *TNF* c.-418 AA   3       6          0.54 (0.13-2.20)                       0.389
  Post        *TNF* c.-418 GG   249     212        \-                                     \-
  Post        *TNF* c.-418 GA   43      67         0.55 (0.36-0.84)                       0.005
  Post        *TNF* c.-418 AA   3       9          0.28 (0.08-1.06)                       0.061
  Pre         *TNF* c.-488 GG   154     173        \-                                     \-
  Pre         *TNF* c.-488 GA   24      37         0.73 (0.42-1.27)                       0.266
  Pre         *TNF* c.-488 AA   1       3          0.37 (0.04-3.64)                       0.397
  Post        *TNF* c.-488 GG   252     224        \-                                     \-
  Post        *TNF* c.-488 GA   41      58         0.63 (0.41-0.97)                       0.038
  Post        *TNF* c.-488 AA   2       6          0.30 (0.06-1.48)                       0.139

Risk association according to patient histopathological types
-------------------------------------------------------------

*NFKB1* heterozygous and variant genotypes were associated with breast cancer risk in invasive ductal carcinoma (IDC) and ductal carcinoma in situ (DCIS), but not in invasive lobular carcinoma (ILC). *IL10* variant genotype was associated with increased breast cancer risk in all three types of breast cancers. On the other hand, *IL8* variant genotype and heterozygous genotypes of both *TNF* polymorphisms were associated with decreased risk of IDC but not of other types of breast cancer ([Table 6](#T6){ref-type="table"}).

###### 

Association between the polymorphisms and breast cancer risk according to histopathological type of patients

  Histo-pathological type\*   Genotype          Cases   Controls   Odds ratio (95% confidence interval)   *P*
  --------------------------- ----------------- ------- ---------- -------------------------------------- ---------
  IDC                         *NFKB1* ins/ins   64      162        \-                                     \-
  IDC                         *NFKB1* ins/del   152     216        1.78 (1.25-2.54)                       0.002
  IDC                         *NFKB1* del/del   130     123        2.68 (1.83-3.91)                       \<0.001
  DCIS                        *NFKB1* ins/ins   12      162        \-                                     \-
  DCIS                        *NFKB1* ins/del   33      216        2.06 (1.03-4.12)                       0.040
  DCIS                        *NFKB1* del/del   26      123        2.85 (1.38-5.88)                       0.005
  ILC                         *NFKB1* ins/ins   17      162        \-                                     \-
  ILC                         *NFKB1* ins/del   25      216        1.10 (0.58-2.11)                       0.767
  ILC                         *NFKB1* del/del   15      123        1.16 (0.56-2.42)                       0.688
  IDC                         *NFKBIA* CC       212     297        \-                                     \-
  IDC                         *NFKBIA* CT       102     162        0.88 (0.65-1.19)                       0.419
  IDC                         *NFKBIA* TT       32      42         1.07 (0.65-1.75)                       0.795
  DCIS                        *NFKBIA* CC       46      297        \-                                     \-
  DCIS                        *NFKBIA* CT       25      162        0.99 (0.59-1.68)                       0.989
  DCIS                        *NFKBIA* TT       0       42         N/A                                    N/A
  ILC                         *NFKBIA* CC       30      297        \-                                     \-
  ILC                         *NFKBIA* CT       20      162        1.22 (0.67-2.22)                       0.510
  ILC                         *NFKBIA* TT       7       42         1.65 (0.68-3.99)                       0.266
                              *IL-8* AA         137     186        \-                                     \-
  IDC                         *IL-8* AT         174     213        1.10 (0.82-1.49)                       0.496
  IDC                         *IL-8* TT         35      102        0.46 (0.29-0.72)                       0.001
  DCIS                        *IL-8* AA         29      186        \-                                     \-
  DCIS                        *IL-8* AT         33      213        0.99 (0.58-1.69)                       0.981
  DCIS                        *IL-8* TT         9       102        0.56 (0.25-1.24)                       0.156
  ILC                         *IL-8* AA         26      186        \-                                     \-
  ILC                         *IL-8* AT         24      213        0.80 (0.44-1.45)                       0.473
  ILC                         *IL-8* TT         7       102        0.49 (0.20-1.17)                       0.108
  IDC                         *IL-10* CC        140     234        \-                                     \-
  IDC                         *IL-10* CT        147     219        1.12 (0.83-1.50)                       0.446
  IDC                         *IL-10* TT        59      48         2.05 (1.33-3.17)                       0.001
  DCIS                        *IL-10* CC        29      234        \-                                     \-
  DCIS                        *IL-10* CT        29      219        1.06 (0.61-1.84)                       0.812
  DCIS                        *IL-10* TT        13      48         2.18 (1.05-4.50)                       0.034
  ILC                         *IL-10* CC        17      234        \-                                     \-
  ILC                         *IL-10* CT        22      219        1.38 (0.71-2.67)                       0.335
  ILC                         *IL-10* TT        18      48         5.16 (2.48-10.73)                      \<0.001
  IDC                         *TNF* c.-418 GG   298     374        \-                                     \-
  IDC                         *TNF* c.-418 GA   43      112        0.48 (0.32-0.71)                       0.001
  IDC                         *TNF* c.-418 AA   5       15         0.41 (0.15-1.16)                       0.095
  DCIS                        *TNF* c.-418 GG   61      374        \-                                     \-
  DCIS                        *TNF* c.-418 GA   10      112        0.54 (0.27-1.10)                       0.092
  DCIS                        *TNF* c.-418 AA   0       15         N/A                                    N/A
  ILC                         *TNF* c.-418 GG   40      374        \-                                     \-
  ILC                         *TNF* c.-418 GA   16      112        1.33 (0.72-2.47)                       0.358
  ILC                         *TNF* c.-418 AA   1       15         0.62 (0.08-4.84)                       0.651
  IDC                         *TNF* c.-488 GG   302     397        \-                                     \-
  IDC                         *TNF* c.-488 GA   41      95         0.56 (0.38-0.84)                       0.005
  IDC                         *TNF* c.-488 AA   3       9          0.43 (0.11-1.63)                       0.219
  DCIS                        *TNF* c.-488 GG   61      397        \-                                     \-
  DCIS                        *TNF* c.-488 GA   10      95         0.68 (0.33-1.386)                      0.293
  DCIS                        *TNF* c.-488 AA   0       9          N/A                                    N/A
  ILC                         *TNF* c.-488 GG   41      397        \-                                     \-
  ILC                         *TNF* c.-488 GA   15      95         1.52 (0.81-2.87)                       0.188
  ILC                         *TNF* c.-488 AA   1       9          1.07 (0.13-8.70)                       0.945

\*IDC -- invasive ductal carcinoma; DCIS -- ductal carcinoma in situ; ILC -- invasive lobular carcinoma.

Risk association according to patient cancer grading
----------------------------------------------------

Increased risk associations were observed for *NFKB1* heterozygous genotype (in Grade 2 and 3 patients), *NFKB1* variant genotype (in all patients), *NFKBIA* variant genotype (in Grade 1 patients), *IL10* heterozygous genotype (in Grade 1 patients), *IL10* variant genotype (in all patients), and *TNF* c.488 heterozygous genotype (in Grade 1 patients). Decreased risk associations were observed for *IL8* heterozygous and variant genotypes, *TNF* c.418 heterozygous genotype, and *TNF* c.488 heterozygous genotype (all in Grade 2 and 3 patients) ([Table 7](#T7){ref-type="table"}).

###### 

Association between the polymorphisms and breast cancer risk according to cancer grading of patients

  Grade\*   Genotype          Cases   Controls   Odds ratio (95% confidence interval)   *P*
  --------- ----------------- ------- ---------- -------------------------------------- ---------
  1         *NFKB1* ins/ins   10      162        \-                                     \-
  1         *NFKB1* ins/del   12      216        0.90 (0.37-2.13)                       0.811
  1         *NFKB1* del/del   20      123        2.63 (1.19-5.83)                       0.017
  2         *NFKB1* ins/ins   44      162        \-                                     \-
  2         *NFKB1* ins/del   101     216        1.72 (1.14-2.59)                       0.009
  2         *NFKB1* del/del   83      123        2.48 (1.60-3.83)                       \<0.001
  3         *NFKB1* ins/ins   39      162        \-                                     \-
  3         *NFKB1* ins/del   97      216        1.86 (1.22-2.84)                       0.004
  3         *NFKB1* del/del   68      123        2.29 (1.45-3.63)                       \<0.001
  1         *NFKBIA* CC       14      297        \-                                     \-
  1         *NFKBIA* CT       16      162        2.09 (0.99-4.40)                       0.051
  1         *NFKBIA* TT       12      42         6.06 (2.62-13.98)                      \<0.001
  2         *NFKBIA* CC       144     297        \-                                     \-
  2         *NFKBIA* CT       67      162        0.81 (0.57-1.15)                       0.253
  2         *NFKBIA* TT       17      42         0.83 (0.45-1.51)                       0.554
  3         *NFKBIA* CC       130     297        \-                                     \-
  3         *NFKBIA* CT       64      162        0.90 (0.63-1.28)                       0.571
  3         *NFKBIA* TT       10      42         0.54 (0.26-1.11)                       0.097
  1         *IL-8* AA         17      186        \-                                     \-
  1         *IL-8* AT         16      213        0.82 (0.40-1.67)                       0.588
  1         *IL-8* TT         9       102        0.96 (0.41-2.24)                       0.935
  2         *IL-8* AA         90      186        \-                                     \-
  2         *IL-8* AT         111     213        0.54 (0.33-0.89)                       0.017
  2         *IL-8* TT         27      102        1.07 (0.76-1.51)                       0.669
  3         *IL-8* AA         85      186        \-                                     \-
  3         *IL-8* AT         104     213        1.06 (0.75-1.51)                       0.709
  3         *IL-8* TT         15      102        0.32 (0.17-0.58)                       \<0.001
  1         *IL-10* CC        5       234        \-                                     \-
  1         *IL-10* CT        28      219        5.98 (2.26-15.77)                      \<0.001
  1         *IL-10* TT        9       48         8.77 (2.81-27.34)                      \<0.001
  2         *IL-10* CC        91      234        \-                                     \-
  2         *IL-10* CT        91      219        1.06 (0.75-1.50)                       0.706
  2         *IL-10* TT        46      48         2.46 (1.53-3.94)                       \<0.001
  3         *IL-10* CC        90      234        \-                                     \-
  3         *IL-10* CT        79      219        0.93 (0.65-1.33)                       0.722
  3         *IL-10* TT        35      48         1.89 (1.15-3.12)                       0.012
  1         *TNF* c.-418 GG   30      374        \-                                     \-
  1         *TNF* c.-418 GA   12      112        1.33 (0.66-2.69)                       0.419
  1         *TNF* c.-418 AA   0       15         N/A                                    N/A
  2         *TNF* c.-418 GG   190     374        \-                                     \-
  2         *TNF* c.-418 GA   33      112        0.58 (0.37-0.88)                       0.012
  2         *TNF* c.-418 AA   5       15         0.65 (0.23-1.83)                       0.421
  3         *TNF* c.-418 GG   179     374        \-                                     \-
  3         *TNF* c.-418 GA   24      112        0.44 (0.27-0.72)                       0.001
  3         *TNF* c.-418 AA   1       15         0.13 (0.01-1.06)                       0.057
  1         *TNF* c.-488 GG   21      397        \-                                     \-
  1         *TNF* c.-488 GA   21      95         4.17 (2.19-7.96)                       \<0.001
  1         *TNF* c.-488 AA   0       9          N/A                                    N/A
  2         *TNF* c.-488 GG   199     397        \-                                     \-
  2         *TNF* c.-488 GA   27      95         0.56 (0.35-0.89)                       0.016
  2         *TNF* c.-488 AA   2       9          0.44 (0.09-2.07)                       0.301
  3         *TNF* c.-488 GG   184     397        \-                                     \-
  3         *TNF* c.-488 GA   18      95         0.40 (0.23-0.69)                       0.001
  3         *TNF* c.-488 AA   2       9          0.48 (0.10-2.24)                       0.350

\*Grade 1 -- well differentiated; Grade 2 -- moderately differentiated; Grade 3 -- poorly differentiated.

Discussion
==========

This study established that the ins/del and del/del genotypes of NFKB1 polymorphism and TT genotype of IL-10 polymorphism significantly increased breast cancer risk, while the TT genotype of IL-8 polymorphism, GA and AA genotypes of TNF c.-418G\>A polymorphism, and GA genotype of TNF c.-488G\>A polymorphism significantly reduced breast cancer risk. Various lines of evidence have found that chronic inflammation was a risk factor for breast cancer development ([@R16]-[@R18]). Inflammation can cause DNA damage, and hence carcinogenesis, by inducing and activating oxidant-producing enzymes ([@R19]). Events that are linked to inflammation, such as postmenopausal status and obesity, have also been associated with an increased breast cancer risk ([@R6]). If inflammation represents an important pathway in carcinogenesis, polymorphisms in the inflammatory response genes could potentially modify cancer predisposition risk.

We analyzed not only the association of individual polymorphisms and breast cancer risk, but also the effects of combinations of functionally related polymorphisms (*NFKB1* and *NFKBIA*; *IL-8* and *IL-10*; and *TNF* c.-418 and c.-488), menopausal status, histopathological type, and cancer grading. To our knowledge, this is the first study investigating the association between *NFKB1* polymorphism and breast cancer risk although there are a few reports on its association with several other cancers. Our findings are in agreement with a study from East China that found that del/del genotype increased the risk of bladder cancer ([@R20]). However, a study in Southern Chinese population ([@R21]) found that the ins/ins genotype increased the risk of colorectal cancer. Our report also presents the first evidence for the association of *NFKBIA* polymorphism with the risk of breast cancer in any Asian population. Thus far, only one study has examined this association but it was conducted in a Caucasian population ([@R22]). Similarly to our study, they found no association between *NFKBIA* polymorphism and breast cancer risk. For *IL-8* polymorphism, one study conducted in East China showed no association with breast cancer risk ([@R23]). Our results are in disagreement with this study, whose genotype distribution deviate significantly from the Hardy-Weinberg equilibrium. However, our results are similar to an Iranian study, which also found an association between the variant genotype of the polymorphism and breast cancer risk ([@R24]). On the other hand, a study from East China showed no association between *IL-10* polymorphism and breast cancer risk ([@R25]), which is different from our results. For *TNF* c.-418 and c.-488 polymorphisms, an Indian study ([@R26]), reported that the AA genotype resulted in an increased breast cancer risk, which is also different from our results. It should be noted, however, that this study had a small sample size with only 40 cases. Similar to our study, Park et al ([@R27]) reported a reduced risk of breast cancer among carriers of the A allele of the polymorphisms. However, this risk reduction was not statistically significant.

In conclusion, our study provided evidence for the association of various inflammatory response gene polymorphisms with the risk of breast cancer in East China. The strengths of the present study are the reasonably large sample size and the detailed combination and stratification analyses performed. The limitations of the study are the small number of polymorphisms studied within each gene and the small sample sizes obtained by stratification according to menopausal status, histopathological type, and cancer grading, which might have led to misleading interpretation. Therefore, further studies by independent research groups are needed to confirm our findings.
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